121 related articles for article (PubMed ID: 15713379)
21. New thiol and sulfodiimine metalloproteinase inhibitors and their effect on human microvascular endothelial cell growth.
Sang QX; Jia MC; Schwartz MA; Jaye MC; Kleinman HK; Ghaffari MA; Luo YL
Biochem Biophys Res Commun; 2000 Aug; 274(3):780-6. PubMed ID: 10924354
[TBL] [Abstract][Full Text] [Related]
22. Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.
Li Q; Fang H; Xu W
Bioorg Med Chem Lett; 2007 May; 17(10):2935-8. PubMed ID: 17433673
[TBL] [Abstract][Full Text] [Related]
23. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
24. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity.
Deschamps AM; Yarbrough WM; Squires CE; Allen RA; McClister DM; Dowdy KB; McLean JE; Mingoia JT; Sample JA; Mukherjee R; Spinale FG
Circulation; 2005 Mar; 111(9):1166-74. PubMed ID: 15723986
[TBL] [Abstract][Full Text] [Related]
25. Effect of NOS inhibition on rat gastric matrix metalloproteinase production during endotoxemia.
Robinson EK; Seaworth CM; Suliburk JW; Adams SD; Kao LS; Mercer DW
Shock; 2006 May; 25(5):507-14. PubMed ID: 16680016
[TBL] [Abstract][Full Text] [Related]
26. Cell-based evidence for aminopeptidase N/CD13 inhibitor actinonin targeting of MT1-MMP-mediated proMMP-2 activation.
Sina A; Lord-Dufour S; Annabi B
Cancer Lett; 2009 Jul; 279(2):171-6. PubMed ID: 19264392
[TBL] [Abstract][Full Text] [Related]
27. Membrane-type 1 matrix metalloproteinase modulates focal adhesion stability and cell migration.
Takino T; Watanabe Y; Matsui M; Miyamori H; Kudo T; Seiki M; Sato H
Exp Cell Res; 2006 May; 312(8):1381-9. PubMed ID: 16473349
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.
Santos MA; Enyedy EA; Nuti E; Rossello A; Krupenko NI; Krupenko SA
Bioorg Med Chem; 2007 Feb; 15(3):1266-74. PubMed ID: 17127067
[TBL] [Abstract][Full Text] [Related]
29. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
30. N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
Lee J; Shim JS; Jung SA; Lee ST; Kwon HJ
Bioorg Med Chem Lett; 2005 Jan; 15(1):181-3. PubMed ID: 15582436
[TBL] [Abstract][Full Text] [Related]
31. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.
Yang SM; Scannevin RH; Wang B; Burke SL; Huang Z; Karnachi P; Wilson LJ; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1140-5. PubMed ID: 18083558
[TBL] [Abstract][Full Text] [Related]
32. Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression.
El Bedoui J; Oak MH; Anglard P; Schini-Kerth VB
Cardiovasc Res; 2005 Aug; 67(2):317-25. PubMed ID: 15885676
[TBL] [Abstract][Full Text] [Related]
33. Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism.
Langlois S; Di Tomasso G; Boivin D; Roghi C; Murphy G; Gingras D; Béliveau R
Exp Cell Res; 2005 Jul; 307(2):452-64. PubMed ID: 15882863
[TBL] [Abstract][Full Text] [Related]
34. MT1-MMP: a potent modifier of pericellular microenvironment.
Itoh Y; Seiki M
J Cell Physiol; 2006 Jan; 206(1):1-8. PubMed ID: 15920734
[TBL] [Abstract][Full Text] [Related]
35. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
[TBL] [Abstract][Full Text] [Related]
36. MT1-MMP: universal or particular player in angiogenesis?
Genís L; Gálvez BG; Gonzalo P; Arroyo AG
Cancer Metastasis Rev; 2006 Mar; 25(1):77-86. PubMed ID: 16680574
[TBL] [Abstract][Full Text] [Related]
37. Rapid assembly of matrix metalloprotease inhibitors using click chemistry.
Wang J; Uttamchandani M; Li J; Hu M; Yao SQ
Org Lett; 2006 Aug; 8(17):3821-4. PubMed ID: 16898826
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 Sep; 16(17):7932-8. PubMed ID: 18718763
[TBL] [Abstract][Full Text] [Related]
39. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity.
Lunter PC; van Kilsdonk JW; van Beek H; Cornelissen IM; Bergers M; Willems PH; van Muijen GN; Swart GW
Cancer Res; 2005 Oct; 65(19):8801-8. PubMed ID: 16204050
[TBL] [Abstract][Full Text] [Related]
40. Recently synthesized class of vinylphosphonates as potent matrix metalloproteinase (MMP-2) inhibitors.
Al-Quntar AA; Baum O; Reich R; Srebnik M
Arch Pharm (Weinheim); 2004 Feb; 337(2):76-80. PubMed ID: 14981663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
